SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 15, 1998
ALFACELL CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 0-11088 22-2369085
(State or other jurisdiction (Commission (IRS EMPLOYER
or incorporation) File Number) Identification)
225 Belleville Avenue, Bloomfield, New Jersey 07003
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (973) 748-8082
________________________________________________________________________________
(Former name or former address, if changed since last report)
<PAGE>
Item 5. Other Events
Alfacell Corporation (the "Company") announced on July 15, 1998 that
preliminary analyses of its randomized Phase III trials for ONCONASE(R) in
pancreatic cancer did not demonstrate a survival benefit over GEMZAR(R) or
5-fluorouracil (5-FU). Based upon the results of the pancreatic cancer trials,
the Company has closed its Phase III program for pancreatic cancer and will not
be filing a New Drug Application (NDA) for this indication.
The Company will now direct its resources toward rapid completion of the
on-going Phase III clinical trial in malignant mesothelioma. More than fifty
percent of patient enrollment has been realized and total patient accrual is
expected by this year end. The malignant mesothelioma trial results are expected
by mid-year 1999.
Certain statements made herein that are not historical facts, contain
forward-looking statements (as such are defined in the Private Securities
Litigation Reform Act of 1995) regarding the Company's future plans, objectives
and expected performance. All such forward-looking statements are based on
assumptions that the Company believes are reasonable, but are subject to a
wide-range of risks and uncertainties and, therefore, there can be no assurance
that actual results may not differ materially from those expressed or implied by
such forward-looking statements. Factors that could cause actual results to
differ materially include, but are not limited to, factors detailed from time to
time in the Company's periodic
<PAGE>
reports and exhibits thereto (including the Annual Report on Form 10-K for the
year ended July 31, 1997) filed with the Securities and Exchange Commission.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: July 15, 1998
ALFACELL CORPORATION (Registrant)
By: /s/ GAIL E. FRASER
--------------------------------
Gail E. Fraser
Vice President Finance and
Chief Financial Officer
